Protein Biomarkers May Differentiate Responders and Non-Responders to Adalimumab, a Tumour Necrosis Factor Inhibitor, in Ankylosing Spondylitis Patients - The Bioefficacy Spa Study
AuthID
P-00T-BDQ
P-00T-BDQ